Our Portfolio List

Here you’ll find a selection of our previous clinical research trials.
Explore the results and learn more about what we do.

A randomized, double-blind, placebo-controlled, multi-center, phase 3 study to determine the safety and efficacy of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or 2 of the knee joint. TG-C is to be administered by a single intra-articular injection to the damaged joint area via ultrasound guidance. Patients will be followed for 24 months for safety and efficacy.

A Study to Determine the Safety and Efficacy of TG-C in Subjects with Kellgren and Lawrence Grade 2 or 3 OA of the Knee

NCT03203330 / TGC12301

Kolon TissueGene, Inc.

July 10, 2024

This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).

Placebo-Controlled Safety Study f Ritlecitinib (Pf-06651600) in Adults with Alopecia Areata (Allegro2a)

NCT04517864 / B7981037

Pfizer

May 7, 2024

$This study was a multi-center, randomized, double-blind, parallel group, active comparator trial designed to evaluate the overall effect of LCZ696 compared to valsartan on cognitive function as assessed by the CogState comprehensive cognitive battery in patients with Heart failure and preserved ejection fraction (HFpEF).$

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients with Chronic Heart Failure

NCT02884206 / CLCZ696B2320

Novartis Pharmaceuticals

May 16, 2022

The purpose of study is to demonstrate the pharmacodynamic (PD) effects of E2027 on cerebrospinal fluid (CSF) cyclic guanosine monophosphate (cGMP) in participants with DLB and PDD with and without amyloid copathology after 9 weeks of treatment.

A Study of E2027 in Participants with Dementia with Lewy Bodies (DLB) or Parkinson's Disease

NCT04764669 / E2027-A001-203

Eisai Inc.

January 27, 2022

A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in participants with non-dialysis-dependent chronic kidney disease (NDD-CKD)

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants with NDD

NCT02680574 / AKB-6548-CI-0015

Akebia Therapeutics

July 31, 2020

A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction of anemia and maintenance of hemoglobin (Hb) in participants with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)

Evaluate Vadadustat for the Correction of Anemia in Participants with Non-dialysis-dependent CKD

NCT02648347 / AKB-6548-CI-0014

Akebia Therapeutics

July 31, 2020

The purpose of this study is to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease.

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with CKD

NCT03036150 / D169AC00001

AstraZeneca

June 12, 2020

The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product in adult patients with asthma.

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

NCT03394989 / U-FS-MU-AS3120

Cipla Ltd.

March 31, 2020

In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events. For administrative purposes the study is divided into two protocol numbers: 1160.129 for all non-EU (European Union) and non-EEA (European Economic Area) countries, and 1160.136 for EU and EEA countries. The total number of patients enrolled in both protocols is estimated to be 48,000 patients, and all these patients will be included in the data analysis for study 1160.129.

GLORIA-AF Registry Program - Second and Third Phases

NCT01468701 / 1160.129

Boehringer Ingelheim

January 10, 2020

An overall study of the cardiovascular outcomes following treatment with ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and established vascular disease. The main objective of this study is to assess the cardiovascular safety of ertugliflozin. This trial includes 3 pre-defined glycemic sub-studies; 1. In participants receiving background insulin with or without metformin, 2. In participants receiving background sulfonylurea monotherapy, and 3. In participants receiving background metformin with sulfonylurea (all fully enrolled).

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus

NCT01986881 / B1521021

Merck Sharp & Dohme LLC

December 27, 2019

$To determine whether treatment with sacubitril/valsartan provides a superior effect on aortic characteristic impedance compared to enalapril in patients with heart failure and reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤ 40%) after 12 weeks of treatment. The primary endpoint is the change in aortic characteristic impedance (Zc = dP/dQ in early systole) between baseline and Week 12.$

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients with Mild to Moderate HF

NCT02874794 / CLCZ696BUS08

Novartis Pharmaceuticals

January 26, 2019

Demonstrate clinical benefit of Toujeo in achieving individualized Healthcare Effectiveness Data and Information Set (HEDIS) glycated hemoglobin (HbA1c) targets (<8% if age >=65 years or with defined comorbidities or otherwise <7%) at 6 months without documented symptomatic (Blood Glucose <=70 mg/deciliter [mg/dL]) and/or severe hypoglycemia at any time of day from baseline to 6 months in uncontrolled insulin naive participants with type 2 diabetes initiating basal insulin therapy in a real world setting.

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo

NCT02451137 / LPS14347

Sanofi

August 9, 2018

The purpose of this study is to evaluate the long-term safety and efficacy of CNTO 136 (sirukumab) in participants with rheumatoid arthritis (RA) who are unresponsive to treatment with modifying antirheumatic drugs (DMARDs) or anti-TNF alpha agents.

Long-term Safety and Efficacy of Sirukumab in Participants with RA

NCT01856309 / CNTO136ARA3004

Janssen Research & Development, LLC

April 30, 2018

The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies.

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary

NCT02155660 / D3251C00004

AstraZeneca

April 9, 2018

Evaluate safety and efficacy of iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®) compared with iron sucrose (Venofer®), in subjects diagnosed with IDA.

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

NCT02940886 / P-Monofer-IDA-03

Pharmacosmos A/S

March 28, 2018

The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes and moderate renal impairment. This study will be conducted at approximately 100 centers from countries across North America and European regions. It is planned to randomize a total of 302 patients.

Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

NCT02413398 / D1690C00024

AstraZeneca

November 7, 2017

A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist

A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Uncontrolled Asthma

NCT02194699 / D2210C00008

AstraZeneca

September 21, 2017

The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF II) is a multicenter, prospective outpatient disease registry to evaluate the utilization of target-specific antithrombotic agents, such as FXa (factor Xa) inhibitors and direct thrombin inhibitors, and associated outcomes. Importantly, the ORBIT AF II registry will permit the collection and analysis of post-approval observational data needed for evaluating the outcomes associated with these new agents when used in broader patient populations outside of clinical studies. The ORBIT-AF II registry will focus on patients with newly diagnosed atrial fibrillation (AF) as well as those who have been recently started on a target-specific oral anticoagulant agent. Taken together, the ORBIT-AF I and ORBIT-AF II registries will offer a broad and contemporary view of AF therapy.

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

NCT01701817 / Orbit AF II

Janssen Scientific Affairs, LLC

July 12, 2017

DS-5565 (mirogabalin) is being studied as treatment for fibromyalgia (FM) pain. Because it is excreted through the kidneys, people who have reduced kidney function will not process the drug as well as with those with normal kidney function, so the dose must be reduced. This study will test two reduced dose levels for both moderately reduced and severely reduced kidney function. The study will test the hypothesis that the drug will be safe and well-tolerated in people who have both fibromyalgia and chronic kidney disease.

Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects with Chronic Kidney Disease

NCT02496884 / DS5565-A-U307

Daiichi Sankyo

July 6, 2017

This is an open-label study of DS-5565 in subjects who either completed participation in a preceding Phase 3 study of DS-5565 in fibromyalgia (FM); i.e. DS5565-A-E309 (NCT02146430), DS5565-A-E310 (NCT02187471), or DS5565-A-E311 (NCT02187159) or are de novo subjects. Eligible subjects will be assigned to receive open-label DS-5565 for 52 weeks. All subjects will receive DS-5565 15 mg once daily (QD) for the first three weeks of the treatment period. After three weeks, subjects may be titrated to 15 mg twice daily (BID) based on protocol-specified criteria.

An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated with Fibromyalgia

NCT02234583 / DS5565-A-E312

Daiichi Sankyo

April 19, 2017

The purpose of this study is to assess ALD403 in the prevention of migraine headaches in chronic migraineurs.

A Multicenter Assessment of ALD403 in Chronic Migraine

NCT02275117 / ALD403-CLIN-005

Alder Biopharmaceuticals, Inc.

November 1, 2016

The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in subjects receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the participant that best describes his or her worst pain over the previous 24 hours.

Treatment of Pain Associated with Fibromyalgia

NCT02146430 / DS5565-A-E309

Daiichi Sankyo

July 14, 2016

The purpose of this study is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of rheumatoid arthritis (RA) in patients with active RA who are unresponsive or intolerant to treatment with anti-TNF-alpha agents.

A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody in Patients with Active Rheumatoid Arthritis

NCT01606761 / CNTO136ARA3003

Janssen Research & Development, LLC

January 12, 2016

This study was designed to determine how well the combination of medication, sumatriptan and naproxen sodium, treats migraine headaches in adolescents 12-17 years old

Migraine Study in Adolescent Patients

NCT00843024 / 107979

GlaxoSmithKline

June 1, 2010

The purpose of this study is to determine the anti-angina effect and dose response of T89, a 2-herb botanical drug product, in patients with chronic stable angina pectoris in the United States.

Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina (T89 phase 2)

NCT00797953 / T89-005-0003-US

Tasly Pharmaceuticals, Inc.

January 1, 2010

The purpose of this study is to evaluate the clinical and laboratory safety of SB-509 when given as a single treatment by an intramuscular injection to subjects with diabetic neuropathy.

Clinical Trial of SB-509-0401 in Subjects with Diabetic Neuropathy

NCT00110500 / SB-509-0401

Sangamo Therapeutics

January 1, 2008

To determine the safety and tolerability of multiple ascending fixed oral doses of SRA-333 in subjects with mild to moderate Alzheimer's disease.

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

NCT00151333 / 3098A1-200

Pfizer

April 1, 2005

EAA-090 is being developed for the treatment of neuropathic pain associated with diabetic neuropathy. It is a selective antagonist that binds competitively to the glutamate site of the N-methyl-D-aspartate (NMDA) receptor.

This study will assess the safety and efficacy of 3 fixed oral doses of EAA-090 compared with placebo in subjects with neuropathic pain associated with diabetic neuropathy.

Study Evaluating EAA-090 in Adult Outpatients with Neuropathic Pain Associated with Diabetic Neuropathy

NCT00073034 / 0912A2-212

Pfizer

December 1, 2004

Our Portfolio List

Here you’ll find a selection of our previous clinical research trials. Explore the results and learn more about what we do.

A Study to Determine the Safety and Efficacy of TG-C in Subjects with Kellgren and Lawrence Grade 2 or 3 OA of the Knee

Placebo-Controlled Safety Study f Ritlecitinib (Pf-06651600) in Adults with Alopecia Areata (Allegro2a)

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients with Chronic Heart Failure

A Study of E2027 in Participants with Dementia with Lewy Bodies (DLB) or Parkinson's Disease

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants with NDD

Evaluate Vadadustat for the Correction of Anemia in Participants with Non-dialysis-dependent CKD

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with CKD

BE Study of Fluticasone Propionate/​Salmeterol Inhalation Powder in Asthma Patients

GLORIA-AF Registry Program - Second and Third Phases

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus

Study of Effects of Sacubitril/​Valsartan vs. Enalapril on Aortic Stiffness in Patients with Mild to Moderate HF

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo

Long-term Safety and Efficacy of Sirukumab in Participants with RA

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary

Iron Isomaltoside/​Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Uncontrolled Asthma

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects with Chronic Kidney Disease

An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated with Fibromyalgia

A Multicenter Assessment of ALD403 in Chronic Migraine

Treatment of Pain Associated with Fibromyalgia

A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody in Patients with Active Rheumatoid Arthritis

Migraine Study in Adolescent Patients

Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina (T89 phase 2)

Clinical Trial of SB-509-0401 in Subjects with Diabetic Neuropathy

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

Study Evaluating EAA-090 in Adult Outpatients with Neuropathic Pain Associated with Diabetic Neuropathy

Here you’ll find a selection of our previous clinical research trials.
Explore the results and learn more about what we do.

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients with Mild to Moderate HF

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)